Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / A long-term open-label safety study of galcanezumab in Japanese patients with migraine.

< BACK TO ARCHIVE


Papers: 2 Jan 2021 - 8 Jan 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Jan 04


Expert Opin Drug Saf


http://www.ncbi.nlm.nih.gov/pubmed/33393835?dopt=Abstract

A long-term open-label safety study of galcanezumab in Japanese patients with migraine.

Authors

A long-term open-label safety study of galcanezumab in Japanese patients with migraine.
Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V
Expert Opin Drug Saf. 2021 Jan 04:1-13.
PMID: 33393835.

Abstract

Because of the burden of migraine in Japan, there is a need for safe and effective preventive treatments. This study assessed the long-term safety and tolerability of galcanezumab in Japanese patients with episodic (EM) or chronic (CM) migraine.
Read This Paper